A Phase 2 interventional study of VXA-CoV2-3.1 and COMIRNATY® in SARS-CoV2 and COVID-19, sponsored by Vaxart. Active, not recruiting at 145 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Vaxart · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 57th largest by planned enrollment of the 1,321 interventional ones that give a count, is one of 74 that started in 2024, is one of 349 in phase 2, reaches primary completion later than 126 of the 208 other live ones, and was the 1,769th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 74 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,485 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Vaxart is the lead sponsor of 23 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 6 (43%) have results posted.
Vaxart has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).
In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain) vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participant has an acute illness as defined by any of the following (note: assessment may be repeated once during screening period) as determined by the site investigator, within 72 hours prior to vaccination:
Administration of , systemic , or other immune-modifying drugs within the following timeframes:
History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine. Such conditions may include but are not limited to:
Any history of:
History of diagnosis or treatment in past 5 years of:
Any history or conditions that may lead to a higher risk of clotting events and/or thrombocytopenia, including:
Presence of any of the following conditions known to increase the risk of thrombosis within 6 months prior to screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants previously immunized against COVID-19 infection will be randomized to receive VXA-CoV2-3.1 (XBB.1.5 vaccine) tablet oral vaccine.
Biological: VXA-CoV2-3.1
Participants previously immunized against COVID-19 infection will be randomized to receive COMIRNATY® (variant matched vaccine 2023-2024 formula) injectable COVID-19 vaccine.
Biological: COMIRNATY®
If no dose-related toxicities are observed, and upon the recommendation of the Data and Safety Monitoring Board following review of Day 31 safety data in the initial safety cohorts (and possibly immunogenicity data), enrollment will continue with the remaining participants who will be randomized to receive a single dose of VXA-CoV2-3.3 (KP.2 vaccine).
Biological: VXA-CoV2-3.3
If no dose-related toxicities are observed, and upon the recommendation of the Data and Safety Monitoring Board following review of Day 31 safety data in the initial safety cohorts (and possibly immunogenicity data), enrollment will continue with the remaining participants who will be randomized to receive a single dose of 2024-2025 formula of COMIRNATY® mRNA COVID-19 injectable vaccine.
Biological: COMIRNATY®
Tablets for oral use.
Intramuscular (IM) injection.
Also known as: Pfizer-BioNTech mRNA Vaccine
Tablets for oral use.
KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic Polymerase Chain Reaction (PCR)-Positive COVID-19 at 14 Days Post-vaccination
Time frame: Up to approximately Day 14
KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 at 12 Months Post-vaccination
Time frame: Up to approximately 12 months
XBB Sentinel Cohorts: Percentage of Participants who Experience any Solicited Local Reactogenicity Through 7 Days Post-vaccination
Time frame: Up to approximately Day 7
XBB Sentinel Cohorts: Percentage of Participants who Experience any Solicited Systemic Reactogenicity Through 7 Days Post-vaccination
Time frame: Up to approximately Day 7
XBB Sentinel Cohorts: Percentage of Participants who Experience Unsolicited Adverse Events (AEs) Through 30 Days Post-vaccination
Time frame: Up to approximately Day 30
XBB Sentinel Cohorts: Percentage of Participants who Experience Treatment-emergent Adverse Events (TEAEs) Through 12 Months Post-vaccination
An AE is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurred after the participant received study treatment. An AE of special interest (AESI) is an AE (serious or non-serious) of scientific and medical concern specific to the sponsor's product or program. Medically attended AEs (MAAEs) are defined as AEs with medically attended visits including hospital, emergency room, urgent care clinic. A serious TEAE (SAE) is any untoward medical occurrence in a clinical study participant after first dose irrespective of a causal relationship with the study treatment that resulted in death, was immediately life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or another medically important serious event.
Time frame: Up to approximately 12 months
XBB Sentinel Cohorts: Percentage of Participants With any Clinically Significant Abnormal Safety Laboratory Results Within 7 Days Pots-vaccination
Time frame: Up to approximately Day 7
KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 Within 14 Days and 12 Months Post-vaccination in Participants with Specified Body Mass Index (BMI)
Time frame: Up to approximately 12 months
KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 within 0 and 180 Days Post-vaccination
Time frame: Up to approximately 180 days
KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 within 181 and 365 Days Post-vaccination
Time frame: Up to approximately 365 days
KP.2 Cohorts: Number of Participants with First Occurrence of Confirmed Asymptomatic PCR-Positive COVID-19 within 14 Days and 12 Months Post-vaccination from Self-administered at Home Tests
Time frame: Up to approximately 12 months
KP.2 Cohorts: Number of Participants with First Occurrence of Presumptive Asymptomatic PCR-Positive COVID-19 from Self-administered at Home Tests
Time frame: Up to approximately 12 months
KP.2 Cohorts: Number of Participants with First Occurrence of Severe PCR-Positive COVID-19 within 14 Days and 12 Months Post-vaccination
Time frame: Up to approximately 12 months
KP.2 Cohorts: Percentage of Participants who Experience any Solicited Local Reactogenicity Through 7 Days Post-vaccination
Time frame: Up to approximately Day 7
KP.2 Cohorts: Percentage of Participants who Experience any Solicited Systemic Reactogenicity Through 7 Days Post-vaccination
Time frame: Up to approximately Day 7
KP.2 Cohorts: Percentage of Participants who Experience Unsolicited AEs Through 30 Days Post-vaccination
Time frame: Up to approximately Day 30
KP.2 Cohorts: Percentage of Participants who Experience TEAEs Through 12 Months Post-vaccination
An AE is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurred after the participant received study treatment. An AESI is an AE (serious or non-serious) of scientific and medical concern specific to the sponsor's product or program. MAAEs are defined as AEs with medically attended visits including hospital, emergency room, urgent care clinic. An SAE is any untoward medical occurrence in a clinical study participant after first dose irrespective of a causal relationship with the study treatment that resulted in death, was immediately life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or another medically important serious event.
Time frame: Up to approximately 12 months
KP.2 Cohorts: Percentage of Participants With any Clinically Significant Abnormal Safety Laboratory Results Within 7 Days Pots-vaccination
Time frame: Up to approximately Day 7
KP.2 Cohorts: Geometric Mean titer (GMT) of SARS-CoV-2 Specific Serum Neutralizing Antibodies (nAb) Post-vaccination
Time frame: Day 1 and Days 31, 91, 181, and 366
KP.2 Cohorts: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific Serum nAb Post-vaccination
Time frame: Day 1 and Days 31, 91, 181, and 366
KP.2 Cohorts: Geometric Mean Concentration (GMC) of Serum Immunoglobulin G (IgG) Binding Antibody (bAb) Against Spike Protein (S) Post-vaccination
Time frame: Days 1, 31, 91, 181, and 366
KP.2 Cohorts: GMFR of Serum IgG Anti-S bAb Post-vaccination
Time frame: Days 1, 31, 91, 181, and 366
KP.2 Cohorts: GMC of Serum Immunoglobulin A (IgA) bAb Against S Post-vaccination
Time frame: Days 1, 31, 91, 181, and 366
KP.2 Cohorts: GMFR of Serum IgA Anti-S Specific bAb Post-vaccination
Time frame: Day 1 and Days 31, 91, 181, and 366
KP.2 Cohorts: GMT of SARS-CoV-2 Specific Saliva nAb Post-vaccination
Time frame: Day 1 and Days 31, 91, 181, and 366
KP.2 Cohorts: GMFR of SARS-CoV-2 Specific Saliva nAb Post-vaccination
Time frame: Day 1 and Days 31, 91, 181, and 366
KP.2 Cohorts: GMC of S-specific Saliva IgA bAb Post-vaccination
Time frame: Days 1, 31, 91, 181, and 366
KP.2 Cohorts: GMFR of S-specific Saliva IgA bAb Post-vaccination
Time frame: Days 1, 31, 91, 181, and 366
KP.2 Cohorts: GMT of SARS-CoV-2 specific Nasal Lining Fluid (NLF) nAb Post-vaccination
Time frame: Days 1, 31, 91, 181, and 366
KP.2 Cohorts: GMFR of SARS-CoV-2 specific NLF nAb Post-vaccination
Time frame: Days 1, 31, 91, 181, and 366
KP.2 Cohorts: GMC of S-specific NLF IgA bAb Post-vaccination
Time frame: Days 1, 31, 91, 181, and 366
KP.2 Cohorts: GMFR of S-specific NLF IgA bAb Post-vaccination
Time frame: Days 1, 31, 91, 181, and 366
KP.2 Cohorts: Percentage of Participants With 2, 3, and 4 Fold Rise in S-specific Serum IgG and IgA bAb, Serum nAb, Saliva IgA bAb, NLF IgA bAb, saliva nAb and NLF nAb Post-vaccination
Time frame: Day 1 and Days 31, 91, 181, and 366
KP.2 Cohorts: Concentration of Intracellular T Cell Cytokine and Cell Surface Marker
Time frame: Days 1, 31, 91, 181, and 366
Showing the first 100 of 145 sites. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for May 2027, 31 months after the start.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 31 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.